LIGHTRICKS
20.8.2024 14:02:26 CEST | Business Wire | Press release
Lightricks, the AI innovators behind Facetune, Videoleap, Photoleap and Popular Pays, announced today that LTX Studio beta, the first AI-driven storyboarding and prototyping platform, is now open to the public. The platform, designed for creative film and marketing professionals, offers real-time, intuitive generative and editing solutions. This announcement includes new features that push the boundaries of visual storytelling, such as increased character and frame control and multi-user collaboration.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240820994937/en/
The LTX Studio platform integrates proprietary AI research from Lightricks engineers with the latest licensed and open-source generative AI models, redefining the creative process. It streamlines video production planning and execution, empowering a wide range of creative professionals—from individual filmmakers to large production companies and advertising agencies—to develop, visualize, storyboard, and pitch their creative concepts into fully crafted film and video projects with unprecedented efficiency and control.
“Releasing LTX Studio to everyone demonstrates our ongoing commitment to the future of video creation through innovative AI-driven tools and our belief in generative AI as a powerful market changer," said Zeev Farbman, CEO and co-founder of Lightricks. “We’ve worked closely with our design partners and creator community to ensure our platform meets their diverse needs better than anything else on the market. We remain committed to exploring new technology and enhancing LTX Studio’s capabilities.”
LTX Studio’s suite of AI features has been refined based on technical and creative feedback from our creative community of more than 35,000 members. The latest updates focus on:
- Enhanced Collaboration: The new Collaboration feature enables creative teams to work together more efficiently with live edit views. LTX Studio plans to release additional collaborative tools, such as commenting and suggestion capabilities, soon.
- Character Acting: LTX Studio now syncs realistic voices with lip movements for any character, allowing users to customize facial gestures and dialogues by referencing real human videos. Users can generate voice from text using AI or upload their original voice files. Future updates will include voice switching for character dialogue and complete scene editing with dialogues.
- Generation Control: Users can now enjoy more control and accuracy in creating their wanted frames and desired motion. Frame Creator lets users craft frames using prompts and scribbles. Keyframe Control generates frames between defined start and end points.
Case Study: Recently, financial services company eToro used LTX Studio to create an AI-generated advertisement that aired during the Paris Olympics. This showcased LTX Studio’s ability to produce high-quality, realistic video content, demonstrating how brands can easily leverage LTX Studio to create compelling visual stories.
Pricing: LTX Studio now offers a tiered pricing model. Users can experience the platform for free with limited generative AI capability, or select from a range of plans based on their monthly generative time needs. Custom plans with premium features are available for enterprises and larger organizations and teams.
Lightricks is embarking on a prolific roadmap for LTX Studio leading into 2025, focusing on leveraging AI to innovate the visual storytelling experience and fuel creativity for professional creators globally. To experience LTX Studio today, join at LTX.Studio.
About Lightricks
Lightricks, an AI-first company, is revolutionizing how visual content is created. With a mission to bridge the gap between imagination and creation, Lightricks is dedicated to bringing cutting-edge technology to the creative and business spaces.
Our AI photo and video generation models, which power our apps and platforms including Facetune, Photoleap, Videoleap, and LTX Studio, allow creators and brands to leverage the latest research breakthroughs, offering endless control over their creative potential. Our influencer marketing platform, Popular Pays, provides creators the ability to monetize their work and offers brands opportunities to scale their content through tailored creator partnerships.
Founded in 2013, Lightricks is backed by prominent investors including Goldman Sachs Growth Equity, Insight Partners and Viola Ventures, who share Lightricks’ enduring commitment to driving the future of content creation.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240820994937/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting tilføjer samarbejdsfirmaet TechSparq25.10.2026 06:09:00 CET | Pressemeddelelse
Andersen Consulting udvider sine kompetencer inden for teknologi og forretningstransformation gennem en samarbejdsaftale med TechSparq, en amerikansk virksomhed, der kombinerer strategi, commerce engineering og ai med praktisk implementering. TechSparq er et digitalt konsulenthus, der tilbyder strategi- og rådgivningstjenester, commerce engineering samt tjenester inden for ai og agentbaseret handel til virksomheder inden for detailhandel og forbrugsgoder, luksus og mode samt e-handel og direkte salg til forbrugere. Virksomheden har hovedkontor i Oregon og kombinerer strategisk planlægning med praktisk implementering for at hjælpe kunderne med at udvikle deres digitale initiativer, kundeoplevelse og driftsmodeller. "Vi etablerede vores virksomhed for at bygge bro mellem dem, der udvikler strategien, og dem, der har ansvaret for at føre den ud i livet," udtalte Dedrick Boyd, stifter af og administrerende direktør for TechSparq. "Vores samarbejde med Andersen Consulting giver os mulighed
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press release
Potential first-in-class GPC3 x 4-1BB bispecific achieves a 36% confirmed response rate at Phase 3 dose and favorable safety profile in heavily pretreated liver cancerBrain-penetrant PRMT5 inhibitor shows promising antitumor and CNS activity in the largest publicly shared MTAP-deficient datasetFirst clinical data of CEA-targeting ADC demonstrates encouraging and sustained responses in CEAhigh NSCLC BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to dise
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom